These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 9788969

  • 1. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
    Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG.
    J Clin Invest; 1998 Oct 15; 102(8):1559-68. PubMed ID: 9788969
    [Abstract] [Full Text] [Related]

  • 2. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
    Véniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, Hellerstein MK, Rudel LL, Walzem RL, Young SG.
    J Clin Invest; 2000 Dec 15; 106(12):1501-10. PubMed ID: 11120757
    [Abstract] [Full Text] [Related]

  • 3. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor.
    Linton MF, Hasty AH, Babaev VR, Fazio S.
    J Clin Invest; 1998 Apr 15; 101(8):1726-36. PubMed ID: 9541504
    [Abstract] [Full Text] [Related]

  • 4. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine.
    Wang HH, Wang DQ.
    Hepatology; 2005 Oct 15; 42(4):894-904. PubMed ID: 16175613
    [Abstract] [Full Text] [Related]

  • 5. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
    Farese RV, Véniant MM, Cham CM, Flynn LM, Pierotti V, Loring JF, Traber M, Ruland S, Stokowski RS, Huszar D, Young SG.
    Proc Natl Acad Sci U S A; 1996 Jun 25; 93(13):6393-8. PubMed ID: 8692825
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist.
    Willnow TE, Sheng Z, Ishibashi S, Herz J.
    Science; 1994 Jun 03; 264(5164):1471-4. PubMed ID: 7515194
    [Abstract] [Full Text] [Related]

  • 7. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
    Véniant MM, Pierotti V, Newland D, Cham CM, Sanan DA, Walzem RL, Young SG.
    J Clin Invest; 1997 Jul 01; 100(1):180-8. PubMed ID: 9202070
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A mouse monoclonal antibody specific for mouse apoB48 and apoB100 produced by immunizing "apoB39-only" mice with mouse apoB48.
    Nguyen AT, Braschi S, Geoffrion M, Fong LG, Crooke RM, Graham MJ, Young SG, Milne R.
    Biochim Biophys Acta; 2006 Feb 01; 1761(2):182-5. PubMed ID: 16551509
    [Abstract] [Full Text] [Related]

  • 10. Studies on the expression of genes encoding apolipoproteins B100 and B48 and the low density lipoprotein receptor in nonhuman primates. Comparison of dietary fat and cholesterol.
    Sorci-Thomas M, Wilson MD, Johnson FL, Williams DL, Rudel LL.
    J Biol Chem; 1989 May 25; 264(15):9039-45. PubMed ID: 2722816
    [Abstract] [Full Text] [Related]

  • 11. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
    Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL.
    J Clin Invest; 1998 Mar 01; 101(5):1084-93. PubMed ID: 9486979
    [Abstract] [Full Text] [Related]

  • 12. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb 01; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 13. Insulin suppression of VLDL apo B secretion is not mediated by the LDL receptor.
    Chirieac DV, Cianci J, Collins HL, Sparks JD, Sparks CE.
    Biochem Biophys Res Commun; 2002 Sep 13; 297(1):134-7. PubMed ID: 12220520
    [Abstract] [Full Text] [Related]

  • 14. Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes.
    Goldberg IJ, Hu Y, Noh HL, Wei J, Huggins LA, Rackmill MG, Hamai H, Reid BN, Blaner WS, Huang LS.
    Diabetes; 2008 Jun 13; 57(6):1674-82. PubMed ID: 18346984
    [Abstract] [Full Text] [Related]

  • 15. Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.
    Johnson LA, Altenburg MK, Walzem RL, Scanga LT, Maeda N.
    Arterioscler Thromb Vasc Biol; 2008 Oct 13; 28(10):1745-52. PubMed ID: 18617647
    [Abstract] [Full Text] [Related]

  • 16. The role of the LDL receptor in apolipoprotein B secretion.
    Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD.
    J Clin Invest; 2000 Feb 13; 105(4):521-32. PubMed ID: 10683382
    [Abstract] [Full Text] [Related]

  • 17. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor.
    Herz J, Qiu SQ, Oesterle A, DeSilva HV, Shafi S, Havel RJ.
    Proc Natl Acad Sci U S A; 1995 May 09; 92(10):4611-5. PubMed ID: 7753850
    [Abstract] [Full Text] [Related]

  • 18. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100.
    Stefansson S, Chappell DA, Argraves KM, Strickland DK, Argraves WS.
    J Biol Chem; 1995 Aug 18; 270(33):19417-21. PubMed ID: 7642623
    [Abstract] [Full Text] [Related]

  • 19. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice.
    Leppänen P, Koota S, Kholová I, Koponen J, Fieber C, Eriksson U, Alitalo K, Ylä-Herttuala S.
    Circulation; 2005 Aug 30; 112(9):1347-52. PubMed ID: 16129816
    [Abstract] [Full Text] [Related]

  • 20. Identification of the proteoglycan binding site in apolipoprotein B48.
    Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Borén J.
    J Biol Chem; 2002 Aug 30; 277(35):32228-33. PubMed ID: 12070165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.